has frequently taken micro cap companies
that were once acorns to a market penetration level of mature oak trees. As
a side benefit, these strategies often assist in building the consumer
markets as well, which in turn can contribute to increased shareholder
equity.
Additionally, MicroCap Management's programs help companies meet
pre-requisite criteria to qualify for listing on premier exchanges such as
NASDAQ, AMEX and NYSE.
Biomoda's patented technology, a non-invasive cytology based assay, is
designed for cancer screening of large populations at a reasonable cost.
Current diagnostic methods for lung cancer, including CT scans and X-rays,
often detect the disease only at more advanced stages and are relatively
expensive.
'/>"/>SOURCE Biomoda, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review2.
China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day3.
Vical Names Andrew de Guttadauro Vice President, Corporate Development4.
Signalife Provides Corporate Update5.
Biomira Announces Plan to Reincorporate in the United States6.
Pressure BioSciences, Inc. Provides Corporate Update7.
The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation8.
Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters9.
ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow10.
MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated11.
New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians